Takeda Pharmaceutical (NYSE:TAK) Insider Elaine Mary Shannon Sells 3,978 Shares of Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Elaine Mary Shannon sold 3,978 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $68,023.80. Following the sale, the insider owned 63,333 shares of the company’s stock, valued at $1,082,994.30. The trade was a 5.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $17.42 on Thursday. The company has a market capitalization of $55.82 billion, a PE ratio of 51.24 and a beta of -0.08. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The company’s 50 day moving average price is $16.49 and its 200 day moving average price is $17.13. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The business had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. Research analysts expect that Takeda Pharmaceutical Co. will post 3.01 EPS for the current fiscal year.

Takeda Pharmaceutical News Summary

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: Insiders continued to hold substantial positions after the transactions, suggesting the sales do not necessarily reflect a loss of confidence in Takeda’s business or outlook. The filings state that the shares were sold to cover tax withholding obligations related to vested equity awards. SEC insider filing
• Neutral Sentiment: Analyst sentiment remains mixed: ratings include two Buys, one Hold and one Sell, resulting in an overall “Hold” consensus. Recent institutional buying has also provided some support, but those purchases were relatively small compared with Takeda’s market capitalization. Takeda stock analysis
• Negative Sentiment: Multiple senior executives and insiders sold a combined 399,? shares at an average price of $17.10. CEO Julie So-Young Kim sold 89,090 shares, Andrew Stewart Plump sold 165,393 shares and General Counsel Natalie Anne Marie Furney sold 30,868 shares. Other insiders also reduced their holdings by approximately 5.9% to 17.8%, which could weigh on investor sentiment despite the tax-related explanation. Takeda insider sales report

Institutional Trading of Takeda Pharmaceutical

Hedge funds have recently bought and sold shares of the stock. Private Trust Co. NA boosted its holdings in shares of Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after acquiring an additional 783 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Takeda Pharmaceutical by 192.2% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after purchasing an additional 1,684 shares during the last quarter. SHP Wealth Management bought a new stake in shares of Takeda Pharmaceutical during the fourth quarter worth $42,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of Takeda Pharmaceutical by 313.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after purchasing an additional 2,328 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after buying an additional 1,292 shares in the last quarter. 9.17% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Finally, Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.